showed that pharmacological inhibition of LIGHT using an LTβR-Fc fusion protein significantly reduced smooth muscle hyperplasia, airway hyperresponsiveness, and lung fibrosis, which identified LIGHT as a target for asthmatic airway remodeling (52). This evidence concerns the gene TNFSF14 and airway hyperresponsiveness.